Apraclonidine Ophthalmic not checked
Alcon Research · FID 123472 · Apraclonidine 0.125% UDPF
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free formulation”In the company’s words, NCT07578363 on ClinicalTrials.gov
- Tested for
- Ocular Hyperemia (2 trials)
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.”In the company’s words, NCT07578363 on ClinicalTrials.gov
- Other names
- FID 123472 · Apraclonidine 0.125% UDPF
Coming up2
- NovPhase 3 trial completes · ClinicalTrials.gov
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2027-01 to 2026-11 · ClinicalTrials.gov NCT07578363
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2026 | An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | |
| Phase 3Recruiting | Feb 2027 | Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026